Your browser doesn't support javascript.
loading
Value of [18F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab.
Graham, Maya S; Krebs, Simone; Bale, Tejus; Domfe, Kwaku; Lobaugh, Stephanie M; Zhang, Zhigang; Dunphy, Mark P; Kaley, Thomas; Young, Robert J.
Afiliación
  • Graham MS; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Krebs S; The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Bale T; Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Domfe K; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Lobaugh SM; College of Medicine, SUNY Upstate Medical University, Syracuse, New York, USA.
  • Zhang Z; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Dunphy MP; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Kaley T; Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Young RJ; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Neurooncol Adv ; 2(1): vdaa050, 2020.
Article en En | MEDLINE | ID: mdl-32642703
BACKGROUND: Treatment of recurrent glioblastoma (GBM) with bevacizumab can induce MRI changes that confound the determination of progression. We sought to determine the value of [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in GBM patients receiving bevacizumab at the time of suspected progression and, thereby, its utility as a potential prognostic adjunct in progressive disease. METHODS: This retrospective study included patients who underwent brain FDG PET within 4 weeks of receiving bevacizumab for recurrent GBM with suspected progression. Volumes-of-interest were placed over the reference lesion with measurement of maximum standardized uptake value (SUVmax), peak standardized uptake value (SUVpeak), metabolic tumor volume, total lesion glycolysis (TLG), and tumor-to-normal contralateral white matter ratios (TNR-WM). Tumors were additionally categorized as non-avid or avid based on qualitative FDG uptake. Associations between baseline variables and overall survival (OS) were examined using univariable and multivariable Cox proportional hazards regression, with P < .05 considered significant. RESULTS: Thirty-one patients were analyzed. Qualitative FDG uptake was significantly associated with OS (P = .03), with a median OS of 9.0 months in non-avid patients versus 4.5 months in avid patients. SUVmax, SUVpeak, TNR-WM, and TLG were significantly associated with OS (P < .001, TLG: P = .009). FDG avidity and SUVmax remained significantly associated with OS (P = .046 and .048, respectively) in the multivariable analysis including age, KPS, and MGMT status. Dichotomizing patients using an SUVmax cutoff of 15.3 was associated with OS (adjusted P = .048). CONCLUSION: FDG PET is a promising imaging tool to further stratify prognosis in recurrent GBM patients on antiangiogenic therapy.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Idioma: En Revista: Neurooncol Adv Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Idioma: En Revista: Neurooncol Adv Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido